SBFM Share Price Performance
Recent SBFM News & Updates
No updates
Sunshine Biopharma, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -1.10
- Gross Margin
- 30.48%
- Net Profit Margin
- -13.88%
- Debt/Equity Ratio
- 0%
Sunshine Biopharma, Inc. Competitors
About SBFM
- Founded
- n/a
- Employees
- 52
- CEO
- WebsiteView website
Sunshine Biopharma, Inc. operates as a pharmaceutical company that focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates through Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products segments. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine The company is based in Fort Lauderdale, Florida.
U.S. Market Performance
- 7 Days: -0.3%
- 3 Months: 14.2%
- 1 Year: 15.7%
- Year to Date: 8.0%
In the last week, the market has been flat, with a notable exception in the Materials sector dropping 4.1%. As for the longer term, the market has risen 16% in the past 12 months. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading